Omnicell (OMCL) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this Omnicell Inc. Would post earnings of $0.41 per share when it actually produced earnings of $0.56, delivering a surprise of 36.59%.Over the last four quarters, the company ha ...

Financial Performance - Total revenues for Q4 2024 were $307 million, an increase of $48 million or 19% year-over-year[3]. - Total revenues for the fiscal year 2024 were $1.112 billion, a decrease of $35 million or 3% compared to 2023[3]. - Total GAAP net income for Q4 2024 was $16 million, or $0.34 per diluted share, compared to a GAAP net loss of $14 million in Q4 2023[4]. - Total non-GAAP net income for Q4 2024 was $28 million, or $0.60 per diluted share, compared to $15 million in Q4 2023[5]. - Net income for the year ended December 31, 2024, was $12,531,000, compared to a net loss of $20,371,000 in 2023[44]. - Operating cash flow for the year ended December 31, 2024, was $187,722,000, slightly up from $181,094,000 in 2023[44]. - Total revenues for Q4 2024 reached $306,879,000, a 18.6% increase from $258,847,000 in Q4 2023[40]. - Product revenues were $182,271,000 in Q4 2024, up from $145,655,000 in Q4 2023, representing a 25.1% growth[40]. - Service revenues increased to $124,608,000 in Q4 2024, compared to $113,192,000 in Q4 2023, marking a 10.8% rise[40]. - Gross profit for Q4 2024 was $141,761,000, a significant increase from $105,404,000 in Q4 2023, reflecting a 34.4% improvement[40]. - GAAP gross profit for Q4 2024 was $141,761 thousand, up from $105,404 thousand in Q4 2023, representing a 34.4% increase[46]. - Non-GAAP gross profit for Q4 2024 was $145,478 thousand, compared to $112,797 thousand in Q4 2023, reflecting a 29.0% increase[46]. - GAAP net income for Q4 2024 was $15,842 thousand, a significant recovery from a net loss of $14,375 thousand in Q4 2023[48]. - Non-GAAP net income for Q4 2024 reached $28,340 thousand, up from $15,013 thousand in Q4 2023, indicating an increase of 88.7%[48]. - Non-GAAP EBITDA for Q4 2024 was $46,424 thousand, compared to $23,742 thousand in Q4 2023, marking a 95.5% increase[50]. - Non-GAAP free cash flow for Q4 2024 was $42,747 thousand, up from $26,042 thousand in Q4 2023, representing a 64.2% increase[50]. - GAAP operating expenses for Q4 2024 were $129,365 thousand, slightly higher than $128,769 thousand in Q4 2023, with a decrease in operating expenses as a percentage of total revenues from 49.7% to 42.2%[46]. - Non-GAAP operating expenses for Q4 2024 were $113,019 thousand, compared to $103,459 thousand in Q4 2023, with a decrease in percentage of total revenues from 40.0% to 36.8%[46]. - The company reported a GAAP operating income of $12,396 thousand for Q4 2024, a recovery from a loss of $23,365 thousand in Q4 2023[46]. - Non-GAAP operating margin improved to 10.6% in Q4 2024 from 3.6% in Q4 2023, indicating enhanced operational efficiency[46]. Future Projections - For 2025, the company projects total revenues between $1.105 billion and $1.155 billion[21]. - The company anticipates long-term growth and consistent GAAP profitability, despite potential risks such as unfavorable economic conditions and competition in the medication management market[27]. - The company is focused on transforming pharmacy and nursing care through outcomes-centric solutions, aiming to deliver clinical and business outcomes across all care settings[24]. - The company is investing in research and development to enhance existing products and develop new solutions, aiming to meet evolving market demands[27]. - The company’s financial guidance includes expectations for product bookings and annual recurring revenue, indicating a focus on sustainable growth[27]. Debt and Cash Management - As of December 31, 2024, cash and cash equivalents were $369 million, with total debt of $341 million[15]. - The company issued $172.5 million in convertible senior notes due 2029 and repurchased $400 million in convertible senior notes due 2025[20]. - Cash and cash equivalents decreased to $369,201,000 as of December 31, 2024, down from $467,972,000 in 2023[42]. - Total assets decreased to $2,120,960,000 in 2024 from $2,226,878,000 in 2023[42]. - Total liabilities decreased to $877,647,000 in 2024 from $1,037,924,000 in 2023[42]. - Omnicell's substantial debt may affect its financial flexibility and access to capital, posing a risk to its growth strategy[27]. Risks and Challenges - The company faces risks related to cybersecurity, including previous ransomware incidents, which could impact its operations and financial performance[27]. - The company is committed to maintaining relationships with its pharmacy customers while navigating regulatory and market challenges[27]. - The company emphasizes the importance of non-GAAP financial measures, which include non-GAAP gross profit, operating expenses, and EBITDA, to provide a clearer view of its core operating performance[28]. - The company expects to continue reporting non-GAAP financial measures, which may differ from GAAP results, highlighting the importance of understanding both[36]. - Omnicell's non-GAAP EBITDA is adjusted for various items, including share-based compensation and acquisition-related expenses, to reflect the company's ongoing operations more accurately[30]. Bookings and Backlog - Total bookings for the year ended December 31, 2024, were $923 million, an increase of 8% year-over-year[8]. - Total backlog as of December 31, 2024, was $1.201 billion, up from $1.143 billion in 2023[9]. New Product Launch - The company announced the launch of OmniSphere, a cloud-native software workflow engine aimed at enhancing medication management[17].

Omnicell (OMCL) is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s Advanced Services offerings is highly encouraging to sustain growth in the upcoming quarters. Efforts to expand into more overseas markets instill optimism. However, adverse macroeconomic challenges and fierce rival pressure could hurt Omnicell’s performance.Currently sporting a Zacks Rank #1 (Strong Buy), OMCL st ...

The market expects Omnicell (OMCL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

Omnicell, Inc. (OMCL) has witnessed strong momentum in the past year. Shares of the company have risen 26.2% against 15.7% decline of the industry. The S&P 500 composite has increased 24.2%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Omnicell develops and markets end-to-end automation solutions for the medication-use process. The company's products enable care providers to improve patient saf ...

Omnicell (OMCL) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The upward trend in estimate revisions for this Omnicell Inc. Reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earning ...

Omnicell (OMCL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Th ...

Omnicell, Inc. (OMCL) recently introduced OmniSphere, a next-generation, cloud-native software workflow engine and data platform. The new platform is designed to leverage the full power of a cloud-native architecture and seamlessly integrate robotics and smart devices to support more secure, data-driven medication management across the continuum of care. OMCL Stock’s Trend Following the NewsSubsequent to the news, OMCL’s share price moved north marginally by 0.1% to $47.14 Tuesday. Earlier this year, Omnice ...

Omnicell (OMCL) closed the last trading session at $41.82, gaining 4.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $53 indicates a 26.7% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $11.75. While the lowest estimate of $37 indicates a 11.5% decline from the current price level, the most optimistic analyst expects the ...

Omnicell, Inc.'s (OMCL) growth in the third quarter of 2024 can be attributed to the company’s long-term development strategy, driven by innovative solutions, expansion into new markets, strategic partnerships and procurement of new technologies. OMCL is on track to meet its 2025 financial goals, supported by increasing tech services and long-term customer partnerships. Stable solvency buoys optimism. However, a headwind from macroeconomic challenges could adversely impact the company’s performance. In the ...